South Australian Neonatal Medication Guidelines

Esmolol
100mg/10mL injection

© Department for Health and Wellbeing, Government of South Australia. All rights reserved.

Note:
This guideline provides advice of a general nature. This statewide guideline has been prepared to promote and facilitate standardisation and consistency of practice, using a multidisciplinary approach. The guideline is based on a review of published evidence and expert opinion.

Information in this statewide guideline is current at the time of publication.

SA Health does not accept responsibility for the quality or accuracy of material on websites linked from this site and does not sponsor, approve or endorse materials on such links.

Health practitioners in the South Australian public health sector are expected to review specific details of each patient and professionally assess the applicability of the relevant guideline to that clinical situation.

If for good clinical reasons, a decision is made to depart from the guideline, the responsible clinician must document the decision made, by whom, and detailed reasons for the departure from the guideline.

This statewide guideline does not address all the elements of clinical practice and assumes that the individual clinicians are responsible for discussing care with consumers in an environment that is culturally appropriate and which enables respectful confidential discussion. This includes:

- The use of interpreter services where necessary,
- Advising consumers of their choice and ensuring informed consent is obtained,
- Providing care within scope of practice, meeting all legislative requirements and maintaining standards of professional conduct, and
- Documenting all care in accordance with mandatory and local requirements

Dose and Indications

To be used only on Cardiology recommendation

Arrhythmias, Supraventricular tachycardia

Intravenous infusion
100microgram/kg/minute, increase in increments of 50-100microgram/kg/minute every 5 minutes until clinical response achieved.

Usual maximum dosage is 200micrograms/kg/minute.

Short-term treatment of post-cardiac surgery hypertension

Intravenous infusion
50micrograms/kg/minute, increase in increments of 25-50micrograms/kg/minute every 5 minutes until desired blood pressure is achieved.

Usual maximum dosage is 200micrograms/kg/minute.

Preparation and Administration

Intravenous

May be given undiluted or diluted to less than 10mg/ml solution with compatible fluid and infuse intravenously. Solution is stable for 24 hours.
Compatible Fluids
Sodium Chloride 0.9%, Glucose 5%, Glucose/sodium chloride combinations

Adverse Effects

**Common**
Hypotension, peripheral ischaemia, vomiting, constipation, agitation, sweating, inflammation (injection site)

**Infrequent**
Bronchospasm, dyspnoea, skin necrosis (injection site)

**Rare**
Severe bradycardia, asystole, cardiac arrest, seizures, respiratory arrest

Monitoring

- Continuous ECG
- Blood pressure

Practice Points

- May cause hypotension which usually reverses within 30 minutes of stopping infusion or reducing dose
- Monitor infusion site for extravasation which can cause skin necrosis and sloughing.
- Contraindicated in second-or third-degree heart block, sinus bradycardia or cardiogenic shock. Heart failure may worsen.

References

Document Ownership & History

Developed by: SA Maternal, Neonatal & Gynaecology Community of Practice
Contact: Health.NeoMed@sa.gov.au
Endorsed by: SA Health Safety and Quality Strategic Governance Committee
Next review due: 03/04/2025
ISBN number: 978-1-76083-176-9
PDS reference: CG333
Policy history:

<table>
<thead>
<tr>
<th>Approval Date</th>
<th>Version</th>
<th>Who approved New/Revised Version</th>
<th>Reason for Change</th>
</tr>
</thead>
<tbody>
<tr>
<td>03/04/2020</td>
<td>V1</td>
<td>SA Health Commissioning and Performance Division</td>
<td>Original approved version</td>
</tr>
</tbody>
</table>

Is this a new policy (V1)? Y
Does this policy amend or update existing policy? N
If so, which version?
Does this policy replace another policy with a different title? N
If so, which policy (title)?